BMS Expands Collaboration with CytomX for US$200 M Upfront

By Natasha Piper

Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)

Published: 8 Apr-2017

DOI: 10.3833/pdr.v2017.i4.2238     ISSN: 1756-7874

Section: Licensing



Bristol-Myers Squibb (BMS) has expanded its strategic collaboration with CytomX Therapeutics to discover novel therapies that will include up to eight additional oncology and non-oncology targets using CytomX’s proprietary Probody™ antibody platform...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details